NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

ACTIV-2: A Study for Outpatients With COVID-19

Phase 2

Completed

Conditions: Coronavirus
Covid19

Interventions: Biological: bamlanivimab 7000mg
Drug: Placebo for Bamlanivimab 7000mg
Biological: bamlanivimab 700mg
Drug: Placebo for Bamlanivimab 700mg
Biological: BRII-196+BRII-198
Drug: Placebo for BRII-196+BRII-198
Biological: AZD7442 (IV)
Biological: AZD7442 (IM)
Drug: Placebo for SNG001
Drug: Placebo for Camostat
Biological: SAB-185 (3,840 Units/kg)
Drug: Placebo for SAB-185 (low dose)
Biological: SAB-185 (10,240 Units/kg)
Drug: Placebo for SAB-185 (high dose)
Biological: BMS-986414 + BMS-986413
Drug: Placebo for BMS-986414 + BMS-986413
Drug: CASIRIVIMAB + IMDEVIMAB
Drug: Placebo for AZD7442 (IV)
Drug: Placebo for AZD7442 (IM)
Drug: SNG001
Drug: Camostat

First Posted Date: 2020-08-19

Last Posted Date: 2024-08-02

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 4044

Registration Number: NCT04518410

Locations: 🇺🇸
Rare Disease Research, LLC. (Site 1248), 1891 Howell Mill Rd.NW, Ste. B, Atlanta, Georgia, United States
🇺🇸
Baltimore VA Medical Center (Site 1258), 10 N. Greene St., Baltimore, Maryland, United States
🇺🇸
Johns Hopkins University (Site 1006), 1830 East Monument Street, Baltimore, Maryland, United States

and more 249 locations

Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum

Recruiting

Conditions: Tuberculosis
HIV Infections

Interventions: Drug: Bictegravir (BIC)
Drug: Doravirine (DOR)
Drug: Tenofovir alafenamide (TAF)
Drug: Cabotegravir (CAB)
Drug: Atazanavir/ritonavir (ATV/r)
Drug: Lopinavir/ritonavir (LPV/r)
Drug: Second-Line TB Treatment
Drug: Dolutegravir (DTG)
Drug: Cobicistat
Drug: First-Line TB Treatment
Drug: Darunavir/ritonavir (DRV/r)
Drug: Ritonavir

First Posted Date: 2020-08-19

Last Posted Date: 2024-08-21

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 325

Registration Number: NCT04518228

Locations: 🇺🇸
Emory University School of Medicine NICHD CRS, Atlanta, Georgia, United States
🇺🇸
Johns Hopkins Univ. Baltimore NICHD CRS, Baltimore, Maryland, United States
🇿🇦
Wits RHI Shandukani Research, Johannesburg, Gauteng, South Africa

and more 34 locations

A Cluster-randomized Trial to EValuate the Efficacy of Wolbachia-InfecTed Aedes Aegypti Mosquitoes in Reducing the Incidence of Arboviral Infection in Brazil (EVITA Dengue)

Not Applicable

Recruiting

Conditions: Dengue Fever

Interventions: Other: Brazilian National Dengue Control Program
Other: Wolbachia-infected Aedes aegypti

First Posted Date: 2020-08-14

Last Posted Date: 2024-12-27

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 3480

Registration Number: NCT04514107

Locations: 🇧🇷
Universidade Federal de Minas Gerais, Instituto de Ciencias Biologicas, Department of Biochemistry and Immunology, Belo Horizonte, Minas Gerais, Brazil

ACTIV-3: Therapeutics for Inpatients With COVID-19

Phase 3

Completed

Conditions: Covid19

Interventions: Biological: LY3819253
Drug: Placebo
Biological: Remdesivir
Biological: VIR-7831
Biological: BRII-196/BRII-198
Biological: AZD7442
Drug: MP0420
Drug: PF-07304814

First Posted Date: 2020-08-06

Last Posted Date: 2023-08-25

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 2753

Registration Number: NCT04501978

Locations: 🇺🇸
University of Maryland Medical Center (Site 301-019), 22 South Greene Street, Baltimore, Maryland, United States
🇺🇸
Ronald Reagan UCLA Medical Center (Site 203-002), 757 Westwood Plaza, Los Angeles, California, United States
🇺🇸
Lutheran Medical Group (Site 301-010), 7916 W. Jefferson Boulevard, Fort Wayne, Indiana, United States

and more 132 locations

Grass Pollen Immunotherapy Plus Dupilumab for Tolerance Induction

Phase 2

Active, not recruiting

Conditions: Allergic Rhinoconjunctivitis
Grass Pollen Allergy

Interventions: Biological: Dupixent®
Drug: Dupixent® Placebo
Biological: Grazax®
Drug: Grazax® Placebo

First Posted Date: 2020-08-06

Last Posted Date: 2024-07-23

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 120

Registration Number: NCT04502966

Locations: 🇬🇧
Royal Brompton Hospital, London, United Kingdom

Adaptive COVID-19 Treatment Trial 3 (ACTT-3)

Phase 3

Completed

Conditions: COVID-19

Interventions: Other: Placebo
Drug: Interferon beta-1a
Drug: Remdesivir

First Posted Date: 2020-07-30

Last Posted Date: 2022-03-14

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 969

Registration Number: NCT04492475

Locations: 🇺🇸
Northwestern Hospital - Infectious Disease, Chicago, Illinois, United States
🇺🇸
University of Illinois at Chicago Division of Infectious Diseases, Chicago, Illinois, United States
🇺🇸
University of Minnesota Medical Center, Fairview - Infectious Diseases and International Medicine, Minneapolis, Minnesota, United States

and more 61 locations

Phase 1 Study of SAR440894 vs Placebo

Phase 1

Active, not recruiting

Conditions: Chikungunya Virus Infection

Interventions: Other: Placebo
Biological: SAR440894

First Posted Date: 2020-06-22

Last Posted Date: 2024-04-22

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 42

Registration Number: NCT04441905

Locations: 🇺🇸
Duke University School of Medicine - Duke Clinical Research Institute - Duke Clinical Research Unit, Durham, North Carolina, United States
🇺🇸
Pharmaceutical Product Development - Orlando Clinical Research Unit, Orlando, Florida, United States
🇺🇸
PPD - Austin Clinical Research Unit, Austin, Texas, United States